Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Diversity, Equity, and Inclusion (DEI) is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
At the event for industry leaders, President Emmanuel Macron positioned France as a global innovator ready to partner with co…
Get five fast facts about albumin and its role in treating serious medical conditions.
Lojewski, who is General Manager of North America, will serve on the industry group, which represents leading global biopharm…
Brand Finance survey results follow CSL’s FY23 rebranding campaign, completion of its CSL Vifor acquisition, increased CSL Pl…
As we observe the International Day of Women and Girls in Science, CSL partners with an organization dedicated to supporting …
With a major acquisition this month, CSL welcomes new employees and expands into iron deficiency; nephrology and rare disease…
A short animation gives an overview of CSL’s businesses and how they are driven by a promise – to patients and to protect pub…
Two leading researchers – and fellowship recipients – will join CSL to work on projects that support the commercialization of…
CSL’s push for decentralized clinical trials is among the top three takeaways from Hill’s recent interview with the Australia…
Our constantly curious Senior Director for Bulk Manufacturing says she’s driven by CSL’s promise to patients and energized by…
Lean into the momentum and innovation that the global pandemic inspired, CSL CEO Paul Perreault told attendees of The Economi…
Forbes Magazine’s recognition demonstrates CSL’s promise to the evolving needs of the workforce.
Americas
Asia Pacific
Middle East
Europe
